Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Drug development

Topic: Brain proteins, microglia and lab models

Plain-language summary

GLP-1RA use was associated with a significantly lower risk of dementia [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.71-0.91, P = .001] and Alzheimer's disease (HR 0.76, 95% CI 0.59-0.98, P = .033) compared with DPP4i use. However, no significant differences were observed in vascular dementia, frontotemporal dementia, Parkinson's disease, extrapyramidal and movement disorders, or dementia with Lewy bodies. GLP-1RA therapy may reduce the risk of dementia and Alzheimer's disease in patients with CKD stage 3 or later, offering potential neuroprotective benefits beyond glycemic control. Research is needed to confirm these findings and optimize treatment strategies for this vulnerable population.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study. In this observational study, people with diabetes and chronic kidney disease who took GLP-1 receptor agonists had a lower risk of being diagnosed with dementia and Alzheimer's disease than those who took DPP4 inhibitors. Reported effect size: HR 0.76.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lee, W.-T., Jing Tong, W. A. N. G., Tsai, M., & Fang, Y. (2026). GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag032

Vancouver

Lee W.-T, Jing Tong WANG, Tsai M, Fang Y. GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag032. PMID: 41697144.

BibTeX

@article{lee2026-41697144,
  author  = {Lee, Wen-Teng and Jing Tong, W. A. N. G. and Tsai, Ming‐Hsien and Fang, Yu‐Wei},
  title   = {{GLP-1 receptor agonists reduce dementia and Alzheimer disease risk in diabetic patients with CKD}},
  journal = {Nephrology Dialysis Transplantation},
  year    = {2026},
  doi     = {10.1093/ndt/gfag032},
  pmid    = {41697144},
  url     = {https://doi.org/10.1093/ndt/gfag032}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In this observational study, people with diabetes and chronic kidney disease who took GLP-1 receptor agonists had a lower risk of being diagnosed with dementia and Alzheimer's disease than those who took DPP4 inhibitors. The study authors say more research is needed to confirm these findings, and no differences were seen for several other brain conditions.

Study details

How this study scored 46/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 3 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 46 of 100.46 of 100 points earned54 not earned

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Nephrology Dialysis Transplantation)
Journal's citation record 2 / 4 Nephrology Dialysis Transplantation: journal h-index 233 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 2 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 2 year(s) since 2026
Impact for its field and year 4 / 6 Cited 9.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Yu‐Wei Fang: h-index 12 (OpenAlex, whole career)
Institution's track record 0 / 3 Fu Jen Catholic University: institution h-index 213 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41697144)
Free to read 0 / 2 Behind a paywall — scores zero
Total 46 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Drug development from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Drug development

See all studies in Drug development →